This article has been reviewed according to Science X's editorial process and policies. Editors have highlighted the following attributes while ensuring the content's credibility:


peer-reviewed publication

trusted source


Under-the-skin implant could treat type I diabetes

Under-the-skin implant could treat Type I diabetes
Design of the SHEATH system. a, Schematic illustrating the creation of the vascularized subcutaneous site achieved by implantation of a catheter 4–6 weeks before transplantation. Removal of the catheter created a vascularized pocket that can be used for implantation of the islet encapsulation devices. b, Schematic illustrating the fabrication of the islet encapsulation device. c,d, Schematic illustrating the concept of the immuno-isolating cell encapsulation system (c). The alginate matrix (blue) protects cells from immune interference while allowing the free passage of glucose and insulin required for therapeutic function (d). e, Illustration of non-encapsulated islets within the vascularized site as an alternative delivery mechanism, suitable only for syngeneic transplants or allogeneic transplants with immunosuppression. Credit: Nature Biomedical Engineering (2023). DOI: 10.1038/s41551-023-01145-8.

A collaboration between researchers from Cornell and University of Alberta, Edmonton, has created a new technique to treat type 1 diabetes: implanting a device inside a pocket under the skin that can secrete insulin while avoiding the immunosuppression that typically stymies management of the disease.

The approach would offer an easier, long-term and less invasive alternative to or traditional transplants that require immunosuppression.

The group's paper is published in Nature Biomedical Engineering.

For the last decade, Minglin Ma, professor of biological and at Cornell, has been trying to develop a better way to control the disease.

In 2017, he unveiled a removeable polymer thread containing thousands of islet cells, protected by a thin hydrogel coating, that could be implanted in a patient's abdomen. The enclosed islets could secrete insulin in response to the body's diminished levels while also receiving a steady flow of nutrients and oxygen to stay healthy. Ma's lab created a more robust version in 2021 that proved effective in controlling blood sugar in diabetic mice for up to six months.

Those projects prompted James Shapiro of the University of Alberta, Edmonton, to reach out about a possible collaboration. Shapiro had created a method for inserting islets in channels just under a person's skin, then applying immunosuppression to protect them.

"I was intrigued by the virtue of Ma's approach as it avoided the need for immunosuppression, and I wondered if we might combine our two innovative strategies to improve ," Shapiro said. "Indeed it worked."

The resulting new system is named SHEATH (Subcutaneous Host-Enabled Alginate THread).

The installation is a two-step process. First, a series of nylon catheters are inserted under the skin, where they remain for four to six weeks—long enough for to form around the catheters. When the catheters are removed, the devices, which are approximately 10 centimeters long, are inserted into the pocket of space the catheters created, and the surrounding vascular system remains intact.

"That channel is a perfect fit for our device," Ma said. "Putting something under your skin is much easier, much less invasive than in the abdomen. It can be done as an outpatient procedure, so you don't have to stay in the hospital. It can be done under local anesthesia."

While additional challenges for the long-term clinical application of the device remain, Ma is hopeful that future versions will be able to last for two to five years before needing to be replaced.

"The challenge is, it's very difficult to keep these islets functional for a long time inside of the body where you have a device, because the device blocks the blood vessels, but the native in the body are known to be in direct contact with vessels that provide nutrients and oxygen," Ma said. "The device is designed in a way that we can maximize the mass exchange of nutrients and oxygen, but we may need to provide additional means to support the cells for a long-term function."

More information: Long-Hai Wang et al, Inflammation-induced subcutaneous neovascularization for the long-term survival of encapsulated islets without immunosuppression, Nature Biomedical Engineering (2023). DOI: 10.1038/s41551-023-01145-8

Journal information: Nature Biomedical Engineering
Provided by Cornell University
Citation: Under-the-skin implant could treat type I diabetes (2023, December 5) retrieved 2 March 2024 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Explore further

Implantable islet cells come with their own oxygen supply


Feedback to editors